Pharming Group (NASDAQ:PHAR) Sees Unusually-High Trading Volume

Pharming Group (NASDAQ:PHAR) saw an uptick in trading volume on Wednesday . 11,273 shares changed hands during trading, an increase of 165% from the previous session’s volume of 4,248 shares.The stock last traded at $8.10 and had previously closed at $8.09.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $37.00 price objective on shares of Pharming Group in a research report on Thursday, August 1st.

Pharming Group Price Performance

The business’s 50 day moving average price is $8.33 and its 200-day moving average price is $9.92. The firm has a market capitalization of $507.77 million, a price-to-earnings ratio of -47.13 and a beta of 0.15.

Pharming Group (NASDAQ:PHAR) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($0.01) earnings per share (EPS) for the quarter. Pharming Group had a negative return on equity of 5.75% and a negative net margin of 4.65%. The firm had revenue of $74.09 million for the quarter, compared to analyst estimates of $71.95 million. During the same quarter last year, the firm earned $0.02 earnings per share. As a group, analysts expect that Pharming Group will post -0.03 earnings per share for the current fiscal year.

Institutional Trading of Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC increased its stake in shares of Pharming Group (NASDAQ:PHAR) by 32.3% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 23,435 shares of the company’s stock after buying an additional 5,725 shares during the period. Silverberg Bernstein Capital Management LLC’s holdings in Pharming Group were worth $196,000 as of its most recent filing with the Securities and Exchange Commission. 0.03% of the stock is owned by institutional investors and hedge funds.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.